These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29017591)

  • 21. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.
    Gisondi P; Bellinato F; Targher G; Idolazzi L; Girolomoni G
    Ann Rheum Dis; 2022 Jan; 81(1):68-73. PubMed ID: 34144965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
    Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
    Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.
    Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
    J Rheumatol; 2017 Aug; 44(8):1151-1158. PubMed ID: 28620063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
    Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
    J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
    Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis.
    Lin YC; Dalal D; Churton S; Brennan DM; Korman NJ; Kim ES; Husni ME
    Arthritis Care Res (Hoboken); 2014 Jan; 66(1):97-103. PubMed ID: 23983044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.
    Coates LC; Rahman P; Psaradellis E; Rampakakis E; Osborne B; Lehman AJ; Nantel F
    Rheumatology (Oxford); 2019 Mar; 58(3):522-526. PubMed ID: 30517715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
    Mease PJ; Young P; Gruben D; Fallon L; Germino R; Kavanaugh A
    Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remission criteria and activity indices in psoriatic arthritis.
    Acosta Felquer ML; Ferreyra Garrott L; Marin J; Catay E; Scolnik M; Scaglioni V; Ruta S; Rosa J; Soriano ER
    Clin Rheumatol; 2014 Sep; 33(9):1323-30. PubMed ID: 24820142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
    van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
    Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America.
    Soriano ER; Zazzetti F; Alves Pereira I; Maldonado Cocco J; Feijó Azevedo V; Guerra G; Bautista-Molano W; Casasola JC; Vega Morales D; Gil DR; Lobosco S; Lawson F
    Clin Rheumatol; 2020 Jun; 39(6):1859-1869. PubMed ID: 31993888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis.
    Shrestha A; Bahce-Altuntas A; Mowrey W; Broder A
    Semin Arthritis Rheum; 2016 Dec; 46(3):286-290. PubMed ID: 27373499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis.
    Appani SK; Devarasetti PK; Irlapati RVP; Rajasekhar L
    Rheumatology (Oxford); 2019 May; 58(5):869-873. PubMed ID: 30590763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study.
    Karadag O; Dalkilic E; Ayan G; Kucuksahin O; Kasifoglu T; Yilmaz N; Koca SS; Yazisiz V; Erten PT; Sayarlioglu M; Terzioglu ME; Erten S; Kalyoncu U
    Clin Rheumatol; 2022 Jan; 41(1):85-94. PubMed ID: 34477993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study.
    Tekin HG; Wu JJ; Burge R; Birt J; Egeberg A
    J Rheumatol; 2019 Jul; 46(7):716-720. PubMed ID: 30824662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.
    Kane D; Stafford L; Bresnihan B; FitzGerald O
    Rheumatology (Oxford); 2003 Dec; 42(12):1460-8. PubMed ID: 14523223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.
    Schoels MM; Aletaha D; Alasti F; Smolen JS
    Ann Rheum Dis; 2016 May; 75(5):811-8. PubMed ID: 26269398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.